Short answer
Axsome Therapeutics, Inc. (AXSM) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Press release covers Axsome’s financial results for the three months ended September 30, 2026.
Axsome Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Axsome’s financial results for the three months ended September 30, 2026
- Operational update accompanies the quarterly results, with substantive details in Exhibit 99.1
Item 8.01 · Other Events
- Updated corporate presentation, signaling refreshed investor messaging or pipeline positioning
- Exhibit 99.2 contains the substantive presentation, requiring review for clinical, regulatory, commercial, or financial updates
Item EX-99.1 · Exhibit EX-99.1
- 3Q revenue $259.7M, up 52% YoY, extending commercial momentum across AUVELITY, SUNOSI and SYMBRAVO
- AUVELITY sales $207.6M, up 53%, with prescriptions up 40% and payer coverage reaching approximately 89%
- Net loss narrowed to $12.9M, or $0.25 per share, from $47.2M, while SG&A rose to $203.1M for commercialization
- Cash $313.9M at September 30, 2026, with management expecting funding into cash-flow positivity
- Pipeline catalysts include AXS-12 FDA action on May 1, 2027, and topline ENGAGE results in 1Q 2027
Item EX-99.2 · Exhibit EX-99.2
- 3Q 2026 net product revenue $259.7M, up 52% YoY, led by AUVELITY $207.6M, up 53%
- AUVELITY Alzheimer’s agitation launch expanding growth beyond MDD, with 21% QoQ new-to-brand prescription growth
- Cash $313.9M against $190M face-value debt, supporting continued investment across seven ongoing Phase 3 trials
- AXS-12 narcolepsy NDA under FDA review, with PDUFA target action May 1, 2027
- Key 2027 catalysts: ENGAGE topline results in 1Q, pediatric ADHD results and multiple Phase 3 readouts in 2H
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axsome Therapeutics, Inc. 8-K filings
Get the next AXSM 8-K as it lands
Follow AXSM for push alerts, or ask the research agent what this filing means.